GI ONCOLOGY

Browse all GI ONCOLOGY
Ep. 4: Next-Line Strategies and Practice Insights for Durvalumab in Gastric and GEJ Cancer

GI ONCOLOGY

Ep. 4: Next-Line Strategies and Practice Insights for Durvalumab in Gastric and GEJ Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Angela Alistar, MD, Steven Maron, MD, MSc, Reetu Mukherji, MD, Raji Shameem, MD

Ep. 4: Sequencing and Next Steps for Zanidatamab in HER2-Positive Gastric Cancer

GI ONCOLOGY

Ep. 4: Sequencing and Next Steps for Zanidatamab in HER2-Positive Gastric Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Geoffrey Ku, MD, Rutika Mehta, MD, MB, MPH, Manish Shah, MD, Nataliya Uboha, MD, PhD

Ep. 3: Balancing Therapy Intensity and Patient Tolerability in Gastric and GEJ Cancer

GI ONCOLOGY

Ep. 3: Balancing Therapy Intensity and Patient Tolerability in Gastric and GEJ Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Angela Alistar, MD, Steven Maron, MD, MSc, Reetu Mukherji, MD, Raji Shameem, MD

Ep. 3: HERIZON-GEA-01: Infusion and GI Management for Zanidatamab

GI ONCOLOGY

Ep. 3: HERIZON-GEA-01: Infusion and GI Management for Zanidatamab

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Geoffrey Ku, MD, Rutika Mehta, MD, MB, MPH, Manish Shah, MD, Nataliya Uboha, MD, PhD

BREAST CANCER

Browse all BREAST CANCER
Ep. 4: Ribociclib and the Evolving Role of Oral SERDs in High-Risk Disease

BREAST CANCER

Ep. 4: Ribociclib and the Evolving Role of Oral SERDs in High-Risk Disease

Laura Huppert, MD, Komal Jhaveri, MD, FACP, Heather McArthur, MD, Hope Rugo, MD, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

BREAST CANCER

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

Laura Huppert, MD, Komal Jhaveri, MD, FACP, Heather McArthur, MD, Hope Rugo, MD, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

BREAST CANCER

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

Laura Huppert, MD, Komal Jhaveri, MD, FACP, Heather McArthur, MD, Hope Rugo, MD, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 4: Early-Stage HR-Positive Breast Cancer: Managing CDK4/6 Inhibitor Sequencing

BREAST CANCER

Ep. 4: Early-Stage HR-Positive Breast Cancer: Managing CDK4/6 Inhibitor Sequencing

Sara Hurvitz, MD, FACP, Sherry Shen, MD, Eleanora Teplinsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

HEMATOLOGY

Browse all HEMATOLOGY
Ep. 4: Managing Fatigue and Phlebotomy Burden in PV With Rusfertide

HEMATOLOGY

Ep. 4: Managing Fatigue and Phlebotomy Burden in PV With Rusfertide

Talha Badar, MBBS, MD, Aaron Gerds, MD, Andrew Kuykendall, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 3: Managing Hematocrit and Symptoms in PV: Dose-Titration Strategies for Rusfertide

HEMATOLOGY

Ep. 3: Managing Hematocrit and Symptoms in PV: Dose-Titration Strategies for Rusfertide

Talha Badar, MBBS, MD, Aaron Gerds, MD, Andrew Kuykendall, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 2: Integrating Rusfertide Into the Polycythemia Vera Treatment Algorithm

HEMATOLOGY

Ep. 2: Integrating Rusfertide Into the Polycythemia Vera Treatment Algorithm

Talha Badar, MBBS, MD, Aaron Gerds, MD, Andrew Kuykendall, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 1: Clinical Insights: New Approaches to Hematocrit Control in Polycythemia Vera

HEMATOLOGY

Ep. 1: Clinical Insights: New Approaches to Hematocrit Control in Polycythemia Vera

Talha Badar, MBBS, MD, Aaron Gerds, MD, Andrew Kuykendall, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

GU ONCOLOGY

Browse all GU ONCOLOGY
Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

GU ONCOLOGY

Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Sia Daneshmand, MD, Chad Reichard, MD, Shilpa Gupta, MD

Ep. 3: Optimizing Perioperative ADC and Immunotherapy in Muscle-Invasive Bladder Cancer

GU ONCOLOGY

Ep. 3: Optimizing Perioperative ADC and Immunotherapy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Sia Daneshmand, MD, Chad Reichard, MD, Shilpa Gupta, MD

Ep. 2: Coordinating Systemic Therapy and Radical Cystectomy in Muscle-Invasive Bladder Cancer

GU ONCOLOGY

Ep. 2: Coordinating Systemic Therapy and Radical Cystectomy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Sia Daneshmand, MD, Chad Reichard, MD, Shilpa Gupta, MD

Ep. 1: NIAGARA: Shifting the Treatment Landscape in Muscle-Invasive Bladder Cancer

GU ONCOLOGY

Ep. 1: NIAGARA: Shifting the Treatment Landscape in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Shilpa Gupta, MD, Sia Daneshmand, MD, Chad Reichard, MD

LUNG CANCER

Browse all LUNG CANCER
Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

LUNG CANCER

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MD, Sarah Goldberg, MD, MPH, Fawzi Abu Rous, MD, Julia Rotow, MD, Susan Scott, MD

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

LUNG CANCER

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MD, Sarah Goldberg, MD, MPH, Susan Scott, MD, Fawzi Abu Rous, MD, Julia Rotow, MD

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

LUNG CANCER

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MD, Luis Raez, MD, FACP, FCCP, FASCO

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

LUNG CANCER

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MD, Susan Scott, MD, Sarah Goldberg, MD, MPH, Fawzi Abu Rous, MD, Julia Rotow, MD